Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Dario Vignali
University of Pittsburgh at Pittsburgh, Department: Microbiology/immun/virology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Bristol-Myers Squibb Company
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
1) Dr. Dario Vignali is an inventor of intellectual property in which LAG-3 plays a part. This intellectual property has been licensed to Bristol-Myers Squibb Company. The institution has determined that since this project involves LAG-3, Dr. Vignali's financial interest in the intellectual property could give rise to an FCOI on this grant.
2) Dr. Dario Vignali holds stock in Bristol-Myers Squibb Company. The institution has determined that since Bristol-Myers Squibb Company conducts research evaluating and/or developing LAG-3 and this project involves LAG-3, Dr. Vignali's financial interest in the company could give rise to an FCOI.
Structure, Function and Mechanistic Analysis of LAG3
Inhibitory receptors, like PD1, CTLA4 and LAG3, are overexpressed in chronic viral infections and cancer, preventing disease clearance, and are thus now major immunotherapeutic targets in the treatment of cancer. However, we still have a very limited understanding of how LAG3, the most recent inhibitory receptor to be targeted in the clinic, works. A greater understanding of the LAG3 mechanism of action may lead to the development of optimal antagonists for the treatment of chronic viral infections and cancer, and agonists for the treatment of autoimmune and inflammatory diseases.
Filed on February 25, 2019.
Tell us what you know about Dario Vignali's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Dario Vignali filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Dario Vignali | University of Pittsburgh at Pittsburgh | Conflict of Interest | Tizona Therapeutics | $80,000 - $99,999 |
| Dario Vignali | University of Pittsburgh at Pittsburgh | Conflict of Interest | Tizona Therapeutics | $40,000 - $59,999 |
| Dario Vignali | University of Pittsburgh at Pittsburgh | Conflict of Interest | Bristol-Myers Squibb Company | $20,000 - $39,999 |
| Dario Vignali | University of Pittsburgh at Pittsburgh | Conflict of Interest | Merck | $20,000 - $39,999 |
| Dario Vignali | University of Pittsburgh at Pittsburgh | Conflict of Interest | Tizona Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.